NCT01304771View on ClinicalTrials.gov

Safety of Synbiotics as Adjuvant to Influenza Vaccine in Elderly

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Synbiotic AKSB

AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide \[FOS\], NutraFlora®).

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Mayo Clinic

OTHER